South Korean biotechnology firm ABL Biotechnologies signed a global licensing and exclusive collaboration agreement with Sanofi to develop and commercialize a new therapy candidate for Parkinson’s disease. 

Swiss drug giant Novartis and Belgian pharma company UCB announced a deal to co-develop and commercialize two products targeting Parkinson’s disease, UCB0599 and UCB7853.

A study by The National Institutes for Quantum Science and Technology in Japan found that a supplement with seven specific amino acids called Amino LP7 appeared to slow brain degeneration and dementia development in mice.

AbbVie’s experimental subcutaneous Parkinson’s disease drug ABBV-951 hit the mark in a 12-week Phase III study in patients with an advanced form of the disease.

Teva Pharmaceutical Industries Ltd. inked a deal to license and develop two of MODAG GmbH’s compounds in neurodegenerative disease.

Paris-based Ipsen inked a licensing deal with Sweden’s IRLAB for mesdopetam, a potential drug for Parkinson’s disease.

Sanofi is halting a pivotal Phase II/III kidney disease trial for venglustat, a novel molecule designed to slow disease progression by inhibiting abnormal accumulation of glycosphingolipids.

Determined to take the company’s next-generation engineered cell therapies to the next level, BlueRock Therapeutics is teaming up with Senti Biosciences with futuristic medicines in mind.  

Shanghai, China-based SciNeuro Pharmaceuticals and U.S.-based Eli Lilly inked an exclusive license deal to develop and commercialize alpha-synuclein targeted antibody treatments in Greater China

RNAi-focused Atalanta Therapeutics launched with $110 million in combined Series A funding and collaboration deals with Genentech and Biogen to address diseases related to the central nervous system, including Huntington’s, Alzheimer’s and Parkinson’s diseases.